Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?

We read with interest the original article by Poula Sousa et  al. [1]. Sousa and colleagues aimed at clarifying the benefits of combination treatment on the maintenance phase of infliximab in CD patients, in comparison with infliximab monotherapy. They brought up very important questions regarding the role of thiopurines in the therapeutic algorithm. In this analysis of the 2-year prospective DIRECT study, the authors investigated the correlation between faecal calprotectin (FC), C-reactive protein (CRP), serum drug levels, and the development of anti-TNF antibodies in adult IBD patients receiving anti-TNF-α treatment.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research